Altis Labs AI Imaging Endpoint Predicts Overall Survival Benefit in Phase 3 Lung Cancer Trial: Data Presented at IASLC WCLC 2026

IPRO Response Rate detected treatment effects missed by ORR, eleven months before primary PFS readout and 26 months before final OS readout in a post hoc analysis. TORONTO — Altis Labs, Inc. (“Altis”), the AI endpoint company accelerating clinical trials, today announced findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in […]